Qualigen Therapeutics (NASDAQ:AIXC) Posts Earnings Results

Qualigen Therapeutics (NASDAQ:AIXC) issued its earnings results on Monday. The company reported ($0.79) EPS for the quarter, FiscalAI reports.

Qualigen Therapeutics Trading Up 9.5%

NASDAQ:AIXC traded up $0.13 on Monday, reaching $1.50. The stock had a trading volume of 88,871 shares, compared to its average volume of 64,027. The stock’s 50-day moving average price is $1.29. The company has a market cap of $30.35 million, a PE ratio of -0.20 and a beta of 0.52. Qualigen Therapeutics has a 12-month low of $0.92 and a 12-month high of $8.81.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Qualigen Therapeutics in a report on Friday, April 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc, a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood.